Bevacizumab plus oxaliplatin-based regimens for the treatment of colorectal cancer.
The anti-angiogenic, monoclonal antibody bevacizumab, in combination with chemotherapy, is proven to prolong survival in metastatic colorectal cancer. Recent data demonstrate that combining bevacizumab with widely used oxaliplatin-containing chemotherapy regimens is a promising strategy for further improving patient outcomes.
Scheithauer
Werner
W
Division of Oncology, Department of Medicine I and Cancer Center, Medical University Vienna, Austria. werner.scheithauer@meduniwien.ac.at
Schmiegel
Wolff
W
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D000068258:Bevacizumab; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D006801:Humans; D009944:Organoplatinum Compounds / Q000008:administration & dosage*; D000077150:Oxaliplatin
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000068258:Bevacizumab